慢性硬膜下血肿经微创穿刺+阿托伐他汀口服治疗的效果、预后及复发

Effect,Prognosis and Recurrence of Minimally Invasive Puncture Combined with Oral Atorvastatin on Chronic Subdural Hematoma

目的分析微创穿刺+阿托伐他汀口服治疗对慢性硬膜下血肿患者的临床效果、预后及复发情况。方法将我院收治的72例慢性硬脑膜下血肿(CSDH)患者根据数字表法随机分为对照组和观察组,每组36例。对照组患者采用钻孔引流术进行治疗,观察组患者实施经微创穿刺+阿托伐他汀口服治疗。对比两组临床疗效、手术时间、住院时间、症状消失时间、治疗后日常生活自理能力(ADL)评分、并发症发生率及术后复发率。结果观察组临床总有效率和对照组比较较高,差异有统计学意义(P<0.05)。观察组手术时间、住院时间、症状消失时间和对照组比较明显较短,观察组ADL评分和对照组比较较高,差异均有统计学意义(P<0.05)。观察组并发症发生率和复发率与对照组比较较低,差异有统计学意义(P<0.05)。结论微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的临床效果优于钻孔引流术,明显降低CSDH并发症发生率和术后血肿复发率,值得临床推广。

Objective To analyze the effect,prognosis and recurrence of minimally invasive puncture combined with oral atorvastatin on chronic subdural hematoma. Methods 72 cases of patients with chronic subdural hematoma（ CSDH）were randomly divided into the control group and the observation group,36 cases in each. The patients in the control group was treated with drilling drainage for treatment,while the patients in the observation group received minimally invasive puncture combined with oral atorvastatin. Clinical efficacy,operation time,hospitalization time,time of symptom disappearance,activity of daily living scale（ ADL） score,incidence of complications and postoperative recurrence rate were compared between the two groups. Results The clinical total effective rate in the observation group was significantly higher than that in the control group（ P 0. 05）. Operation time,hospitalization time and time of symptom disappearance in the observation group was significantly shorter than that in the control group,but the ADL score in the observation group was significantly higher than that in the control group（ P 0. 05）. Incidence of complications and recurrence rate in the observation group was significantly lower than that in the control group（ P 0. 05）. Conclusion The clinical effect of minimally invasive puncture combined with oral atorvastatin on chronic subdural hematoma is better than drilling drainage,which can significantly reduce the incidence of CSDH complications and postoperative hematoma recurrence rate. It is worthy of clinical application.